TMB testing should be routinely done in MSI‐H CRC, and TMB ≥ 35 mut/MB samples should be screened for NTRK and RET fusions as an enrichment strategy to provide additional treatment for NTRK+ and RET+ CRC patients. This evidence concerns the gene RET and colorectal carcinoma.